Lancet
-
Randomized Controlled Trial Multicenter Study
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Correction of hyperglycaemia and prevention of glucotoxicity are important objectives in the management of type 2 diabetes. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption in an insulin-independent manner. We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin. ⋯ Bristol-Myers Squibb and AstraZeneca.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diabetes treatments are needed that are convenient, provide effective glycaemic control, and do not cause weight gain. We aimed to test the hypothesis that improvement in haemoglobin A(1c) (HbA(1c)) achieved with once weekly exenatide was superior to that achieved with insulin glargine titrated to glucose targets. ⋯ Amylin Pharmaceuticals; Eli Lilly and Company.
-
Randomized Controlled Trial Multicenter Study
Parent-mediated communication-focused treatment in children with autism (PACT): a randomised controlled trial.
Results of small trials suggest that early interventions for social communication are effective for the treatment of autism in children. We therefore investigated the efficacy of such an intervention in a larger trial. ⋯ UK Medical Research Council, and UK Department for Children, Schools and Families.